Rasagiline ethanedisulfonate: an inhibitor for monoamine oxygenase B (MAO(B)).
Rasagiline is a selective and potent drug used for the treatment of Parkinson's disease. The first crystal structure of a salt of rasagiline, the title compound, bis[(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-aminium] ethanedisulfonate, 2C(12)H(14)N(+).C(2)H(4)O(6)S(2)(-), was determined from crystals grown by gas diffusion. The compound has monoclinic (C2) symmetry. The ethane group of the ethanedisulfonate anion is disordered over three positions. The C(2)-symmetric ethanedisulfonate anions are connected by four N-H...O hydrogen bonds to four rasagiline cations. This leads to large 18-membered rings which are arranged in ladders in the [010] direction. The extended hydrogen-bonding architecture may explain the stability of the structure. Rasagiline ethanedisulfonate is nonhygroscopic. During a polymorph screen, no hydrates, solvates or polymorphs were found.
Brüning
Jürgen
J
Institute of Inorganic and Analytical Chemistry, University of Frankfurt, Max-von-Laue-Strasse 7, D-60438 Frankfurt am Main, Germany. bruening@chemie.uni-frankfurt.de
Bats
Jan W
JW
Schmidt
Martin U
MU
D003460:Crystallization / Q000379:methods; D018360:Crystallography, X-Ray; D006860:Hydrogen Bonding; D007189:Indans / Q000138:chemical synthesis* / Q000737:chemistry*; D015394:Molecular Structure; D008996:Monoamine Oxidase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry; D010300:Parkinson Disease / Q000188:drug therapy
D007189:Indans; D008996:Monoamine Oxidase Inhibitors; C031967:rasagiline